Publications
Links to our latest financial and sustainability reports and other recent publications.
Investors
Full-Year 2024 Financial Results
Grifols’ fourth quarter and year-end 2024 results.
Showing 223 search results
Press release
Grifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’
Press release
Grifols Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients
Press release
Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029
Press release
Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow
Press release
Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner
Press release
Grifols completes enrollment of second cohort in first-in-human Alpha-1 15% subcutaneous option for treating alpha1-antitrypsin deficiency
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.